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RESEARCH NOTE
Clinicopathologic features and prognostic 
grouping of gastrointestinal stromal tumors 
(GISTs) in Pakistani patients: an institutional 
perspective
Atif Ali Hashmi1, Mahrukh Faraz1, Zareeha Nauman1, Muhammad Usman Qureshi2, Shumaila Kanwal Hashmi3, 
Hira Fatima Waseem1, Muhammad Muzzammil Edhi4, Naveen Faridi1 and Amir Khan5* 
Abstract 
Objectives: Gastrointestinal stromal tumors (GISTs) are rare tumors of gastrointestinal tract, prognosis of which 
largely depends upon histopathologic characteristics of resection specimens, which were not widely studied in our 
population. Therefore we aimed to evaluate the histopathologic characteristics of GISTs in our population and their 
prognostic grouping according to college of American pathologist’s guidelines.
Results: Mean age of patients was 53.4 years (18–71 years). 92% of cases were of primary GISTs and stomach was the 
most common site (57.7%). 75% of cases were of spindle cell morphology and 53.8% belonged to high risk prognostic 
group. Comparison of stomach and intestinal GISTs showed that intestinal GISTs were found to be of high grade (70%) 
and of high risk prognostic group (75 and 80%) compared to stomach GISTs (43% were of high risk prognostic group), 
however this finding was not statistically significant. GISTs are infrequent gastrointestinal tumors but early diagnosis 
and identification of adverse histological features are key to successful treatment. We found a large majority of GISTs 
to be located in stomach, however intestinal GISTs were found more likely to be associated with adverse prognostic 
parameters. However more large scale studies are warranted to establish this finding.
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Introduction
Gastrointestinal stromal tumors (GISTs) are the most 
common mesenchymal tumors of the gut, however 
overall they still account for < 1% of all gastrointestinal 
tumors [1]. The clinical signs and symptoms of GISTs 
are non-specific abdominal discomfort and distention, 
therefore the diagnosis and treatment is usually delayed 
leading to therapy failures and high morbidity and mor-
tality rates. The incidence of GISTs at present is about 15 
cases in 1 million in the United States and about 11 cases 
in one million in Northern Europe. Although, the inci-
dence of GISTs before 2000 is unknown; but the growing 
number of presenting cases has led to increased research 
about this subject [2, 3]. The incidence of GISTs in our 
country is unknown as large scale studies have not been 
conducted.
Morphologically, the features of GIST resemble that 
of leiomyoma and leiomyosarcoma and were previously 
classified as such [4]. Almost all recent researches have 
reached to the conclusion that GISTs can occur anywhere 
throughout the digestive tract but most number of GIST 
cases were recorded in the stomach [5].
The pathologic parameters of GISTs in resection speci-
mens are important in guiding post-operative manage-
ment and determining prognosis of the patients, however 
these features have not been widely studied in our popu-
lation. Only a few studies have been conducted in Paki-
stan. Ud Din et al. evaluated 255 cases of GIST and found 
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62.3 gastric, 81.8% duodenal, 68% small intestinal, 72% 
colorectal and 89% GISTs to be of high risk category [6]. 
Similarly Mushtaq et al. performed risk stratification on 
36 cases of GIST. They found seven patients to fall into 
low risk, ten patients intermediate risk, and 19 patients in 
high risk groups. There were no patients in very low risk 
group [7]. Therefore in this study we aimed to evaluate 
clinicopathologic and prognostic parameters of GISTs in 
our population which can help in devising personalized 
therapeutic regimens for loco-regional population.
Main text
Materials and methods
A total of 52 cases of GISTs diagnosed and treated at Lia-
quat National hospital were included in the study from 
2011 till 2016. An approval from institutional ethical 
review committee was taken antecedent to conducting 
the study. All cases were biopsy proven prior to definite 
resection. After pre-operative workup, definite resection 
was performed and specimens were sent to the pathol-
ogy department. Gross and microscopic features of all 
tumors were recorded including tumor size, site, tumor 
morphology, grade, number of mitosis and prognostic 
group according to College of American Pathologists 
(CAP) guidelines.
Immunohistochemistry
Immunohistochemical markers including CKAE1/3, 
ASMA, S100, CD34 and CD117 were performed by 
DAKO envision method and slides were interpreted by 
experienced pathologists. For CD117 IHC, polyclonal 
Rabbit anti-human CD117, c-kit antibody was used pur-
chased from DAKO and IHC was performed according 
to DAKO envision method. Moderate to strong membra-
nous staining in more than 10% tumor cells is considered 
positive. For CD34, FLEX monoclonal anti-human CD34 
class II, clone QBEnd 10, ready to use antibody was used. 
For S100 IHC, FLEX polyclonal rabbit Anti-S100 ready 
to use antibody was purchased from DAKO. Similarly, 
for ASMA IHC, monoclonal anti-human Smooth muscle 
actin, clone 1A4 antibody was used and performed using 
DAKO envision kit according to manufacturer’s recom-
mendations. Moderate to strong cytoplasmic staining in 
more than 10% tumor cells was considered positive for 
ASMA, S100 and CD34.
Statistical analysis
Statistical package for social sciences (SPSS 21) was used 
for data compilation and analysis. Mean and standard 
deviation were calculated for quantitative variables. Fre-
quency and percentage were calculated for qualitative 
variables. Chi square was applied to determine associa-
tion. P-value of ≤ 0.05 was considered as significant.
Results
Mean age of patients was 53.4 years (18–71 years) with a 
slight male predominance. 92% of cases were of primary 
GISTs and stomach was the most common site (57.7%). 
75% of cases were of spindle cell morphology and 53.8% 
belonged to high risk prognostic group as shown in 
Table 1. Table 2 shows the comparison of GISTs at various 
sites of digestive tract. Out of 48 cases of primary GISTs, 
30 cases were seen in stomach, 10 in small intestine and 8 
in large intestine. Out of 30 GISTs of stomach, 20 were in 
the age group of > 50 years, 9 were seen in the age group 
of 31–50 years and only 1 case of stomach GIST was seen 
in age group of < 30 years. Similarly, in the small and large 
intestine, the larger number of cases were seen in the age 
group of > 50  years. The gender predominance was not 
much appreciated, as equal number of cases of stomach 
GIST was seen in both male and female. However, the 
small and large intestines GISTs were seen to be more 
common in males, however this finding was not statisti-
cally significant. Majority of the tumors were greater than 
10 cm in size, however most GISTs in the stomach were 
found to be 5–10 cm in size and most GISTs in the small 
and large intestine were greater than 10  cm in size. 37 
out of 48 cases were of spindle cell morphology. 20 out of 
30 cases of stomach GIST were of spindle cell morphol-
ogy, while 3 were epitheloid (Fig. 1) and 7 were of mixed 
morphology. Almost all cases of small and large intestine 
GIST were of spindle cell variety (Additional file 1: Figure 
S1). 27 cases fell in the category of high risk category, 5 
in the moderate risk, 11 in the low risk and 5 in the very 
low risk. Majority of the cases displayed a mitotic activity 
of greater than 5/50 HPF as a whole. 34 out of 46 tumors 
were CD34 positive and 46 out of 48 were CD117 posi-
tive. 12 out of 40 were positive for S100 and 19 out of 43 
were positive for ASMA. Hence, majority of the tumors 
were positive for CD34 and CD117 and negative for S100 
and ASMA as shown in Table 3.
Discussion/conclusion
GISTs have long been known to be mesenchymal tumors 
of the gastrointestinal tract [2, 8]. Historically, they were 
considered rare tumors mainly due to the reason that 
they were mostly misdiagnosed owing to the similari-
ties they shares with leiomyomas, leimyosarcomas and 
schwannomas [9]. The misdiagnosis led to a bad progno-
sis and treatment failures. However, the attempts made 
in the recent years to better understand the occurrence, 
incidence and morphology of GIST has established the 
fact that they are the most common mesenchymal tumor 
of the GIT [1]. They can occur anywhere along the length 
of the GIT, most common location of GIST occurrence 
being the stomach [5].
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In this study, we specifically compared the general 
characteristics of GIST with respect to the location and 
the histochemical markers (as they have proved to be in 
an essential tool for the diagnosis of GIST) and compared 
them with previously published literature.
Although most of the literature quotes the presence 
of GIST in esophagus, stomach, intestine, rectum and 
mesentery; in this study of 48 cases of primary GIST, 
the occurrence was seen in stomach, small intestine and 
large intestine only. As per previous studies, stomach 
predominated with 62.5% followed by small intestine 
(20.8%) and large intestine (16.7%). This was consistent 
with the findings of most of the other Asian literature.
GISTs were seen to be more common in the older 
age adults of greater than 50 years and very rarely seen 
in young adults of less than 30 years. Some cases were 
also seen in the age group of 30–50 but it was not so 
commonly seen in this age group, mean age of stomach 
GIST being 54.50, 52.10 of small intestine and 55.25 
of large intestine. Although not statistically significant 
(P = 0.785) but in accordance with other studies done, 
we can say that GIST is most likely to occur in older age 
adults of greater than 50 years [10–12].
Male and female genders were equally affected by 
stomach GIST (50% cases were reported in both), how-
ever the intestinal GIST were predominantly seen in 
males than females (80% vs 20% in small intestine and 
75% vs 25% in large intestine). Although other Asian 
studies did show slight male to female dominance [10, 
11, 13], in this study no statistical significance was seen 
(P = 0.159).
GISTs usually involve the entire thickness of the gastro-
intestinal wall [14, 15], this owes to the fact that they are 
usually larger in size, as established in this study where 
majority of the tumors were greater than 10  cm and 
scarcely less than 5 cm. The reason behind the large size 
of the tumor might be its relatively silent clinical course 
[10]. However, the mean size of the tumor in the stomach 
was seen to be 8.96 and 10.20 and 10.28 in the small and 
large intestine respectively. Although, not statistically 
significant (P = 0.570) it can be noticed that majority of 
the tumors in the stomach ranged from 5 to 10 cm in size 
and majority of the intestinal tumors were greater than 
10 cm. Some other Asian studies have also mentioned the 
mean size of the tumor to be > 5 cm [13, 16].
On histology, the majority tumors composed of spin-
dle cells (77%) arranged in interlacing pattern forming 
whorls, with abundant eosinophilic cytoplasm. Epitheloid 
and mixed varieties were rarely seen, however among 
these two, the mixed variety predominated (10% and 
35.8% respectively); although epitheloid type has been 
mentioned to be more common than mixed in the pre-
vious literatures [15] but our finding was consistent with 
the findings of Asian literature in which mixed variety 
predominated [10, 11]. Nonetheless, spindle variety was 
most common finding in all studies. Although not statis-
tically significant, but it was noted that the stomach con-
tained all three types of morphology patterns while 100% 
of the cases of the small intestinal GISTs were of spindle 
cell morphology and the large intestinal GISTS were seen 
Table 1 Clinicopathologic characteristics of gastrointestinal 
tumors (GISTs)
Characteristic Frequency (%)
Gender
 Male 32 (61.5%)
 Female 20 (38.51%)
Age (years)
 Mean 53.4 (18–71 years)
 Age groups (years)
  < 30 3 (5.8%)
  31–50 18 (34.61%)
  > 50 31 (59.6%)
Primary/metastatic
 Primary 48 (92.3%)
 Metastasis 4 (7.74%)
Site
 Stomach 30 (57.7%)
 Small intestine 10 (19.2%)
 Large intestine 08 (15.4%)
 Liver 04 (7.7%)
Size (cm)
 Mean 9.4 (2–16)
 Size groups (cm)
  < 2 1 (1.9%)
  2–5 6 (11.5%)
  5–10 20 (35.5%)
  > 10 22 (42.3%)
Morphology
 Spindle 39 (75%)
 Eptheloid 4 (7.5%)
 Mixed 9 (17.3%)
Grade (mitotic activity)
 Low grade (< 5/50HPFs) 23 (44.2%)
 High grade (> 5/50HPFs) 29 (55.8%)
Necrosis
 Present 10 (19.2%)
 Absent 42 (80.8%)
Prognostic groups
 Very low risk 5 (9.63%)
 Low risk 11 (21.2%)
 Moderate risk 5 (9.6%)
 High risk 28 (53.8%)
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to have spindle and mixed morphology (87.5 and 12.5% 
respectively).
According to Asian studies, most of the GISTs overall 
were low grade tumors [11] and most showed high risk 
features followed by intermediate and low risk [12, 13, 
17]. In our study, majority of the stomach GISTs were 
seen to be of high risk (43.3%), followed by low risk, very 
low risk and moderate risk. However, the greatest high 
risk tumors were in the small intestine (80%) and large 
intestine (75%).
For the purpose of studying the immunohistochemi-
cal features of the GISTs, two types of antibodies were 
used: one with high specificity for GISTs, such as CD117 
and CD34, and other which are more specific for smooth 
muscle tumors and neural tumors (ASMA and S-100), as 
these two types of tumors are the ones which are most 
often misdiagnosed as GISTs.
S-100 was positive in 12 cases, negative in 28, not 
performed in 8. ASMA was positive in 19 cases, nega-
tive in 24 and not performed in 5. CD34 was positive in 
34 cases, negative in 12 and not performed in 2. CD117 
was positive in 46 cases and negative in 2. These find-
ings are consistent with many other Asian studies in 
which CD117 and CD34 positivity has been seen in 
most GISTs, followed by ASMA and S-100 [10, 13, 16, 
18].
While, most of the stomach GISTs were negative for 
ASMA (70.8%) and S-100 (64.3%) and positive for CD34 
and CD117 (as well as most of small intestine tumors 
were positive for both), most of the large intestine GISTs 
were seen to be positive for ASMA (26.3%) and nega-
tive for CD34 (41.7%). Most of the spindle cell variety 
was negative for ASMA (83.3%) and positive for CD34 
(73.5%) and most of the epitheloid and mixed variety 
Table 2 Comparison of clinicopathologic features of gastrointestinal stromal tumors (GISTs) of various sites
Variables Stomach Small intestine Large intestine P-value
N (%) N (%) N (%)
Age (years)
 Mean ± SD 54.50 ± 11.99 52.10 ± 15.53 55.25 ± 14.29 0.852
Age groups (years)
 ≤ 30 1 (3.3) 1 (10) 0 0.785
 31–50 9 (30) 4 (40) 3 (37.5)
 > 50 20 (66.7) 5 (50) 5 (62.5)
Gender
 Male 15 (50) 8 (80) 6 (75) 0.159
 Female 15 (50) 2 (20) 2 (25)
Size
 Mean ± SD 8.96 ± 3.94 10.20 ± 4.75 10.28 ± 3.11 0.570
Size groups (cm)
 ≤ 2 0 1 (10) 0 0.287
 2.1–5 4 (13.3) 1 (10) 1 (12.5)
 5.1–10 15 (50) 2 (20) 2 (25)
 > 10 11 (36.7) 6 (60) 5 (62.5)
Morphology
 Spindle cell 20 (66.7) 10 (100) 7 (87.5) 0.318
 Eptheloid 3 (10) 0 0
 Mixed 7 (23.3) 0 1 (12.5)
Prognostic group
 Very low risk 4 (13.3) 1 (10) 0 0.214
 Low risk 10 (33.3) 0 1 (12.5)
 Moderate risk 3 (10) 1 (10) 1 (12.5)
 High risk 13 (43.3) 8 (80) 6 (75)
Grade (mitotic activity)
 Low grade (≤ 5/50HPFs) 15 (50) 3 (30) 5 (62.5) 0.456
 High grade (> 5/50HPFs) 15 (50) 7 (70) 3 (37.5)
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were positive for ASMA (10.5 and 26.3%) and CD34 neg-
ativity was noticed in most epitheloid type variety. Most 
of the high risk tumors were negative (62.5%) and low 
risk tumors were positive (31.6%) for ASMA.
A statistically significant finding was seen in CD34 
positivity with respect to site of the tumor (P = 0.013) 
and CD117 positivity with respect to the morphology 
of the tumor (P = 0.024); other findings however, were 
not statistically significant.
Liu et  al. compared 300 cases of duodenal GISTs 
with gastric GISTs and found them to be significantly 
associated with worse prognostic features [19]. Simi-
larly Zhu et al. compared colorectal GISTs with gastric 
GISTs. They found rectal GISTs to be associated with 
improved overall survival while colonic GISTs were 
associated with worse overall survival [20]. On the 
other hand Feng et  al. studied small intestinal GISTs 
and found jejunal and ileal GISTs to be comparable in 
terms of prognosis [21].
Limitations
GISTs are infrequent gastrointestinal tumors but early 
diagnosis and identification of adverse histological fea-
tures are key to successful treatment. We found a large 
majority of GISTs to be located in stomach, however 
intestinal GISTs were found more likely to be associ-
ated with adverse prognostic parameters. One of the 
major limitations of the study was small sample size 
and lack of clinical follow up to determine disease free 
survival and recurrence. Therefore we suggest that, 
Fig. 1 Gastrointestinal stromal tumor, Epitheloid subtype: A–C H&E sections showing sheets of epitheloid cells with marked atypia. D Diffuse 
expression of CD117 noted in tumor cells
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more large scale studies are warranted to establish the 
findings of our study.
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